A machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations.

AUC Model informed precision dosing Monte Carlo simulations Pharmacometrics TDM XGBoost artificial intelligence daptomycin machine learning population pharmacokinetics

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
19 Mar 2024
Historique:
medline: 19 3 2024
pubmed: 19 3 2024
entrez: 19 3 2024
Statut: aheadofprint

Résumé

Daptomycin is a concentration-dependent lipopeptide antibiotic for which exposure/effect relationships have been shown. Machine learning (ML) algorithms, developed to predict the individual exposure to drugs, have shown very good performances in comparison to maximum a posteriori Bayesian estimation (MAP-BE). The aim of this work was to predict the area under the blood concentration curve (AUC) of daptomycin from two samples and a few covariates using XGBoost ML algorithm trained on Monte Carlo simulations. Five thousand one hundred fifty patients were simulated from two literature population pharmacokinetics models. Data from the first model were split into a training set (75%) and a testing set (25%). Four ML algorithms were built to learn AUC based on daptomycin blood concentration samples at pre-dose and 1 h post-dose. The XGBoost model (best ML algorithm) with the lowest root mean square error (RMSE) in a 10-fold cross-validation experiment was evaluated in both the test set and the simulations from the second population pharmacokinetic model (validation). The ML model based on the two concentrations, the differences between these concentrations, and five other covariates (sex, weight, daptomycin dose, creatinine clearance, and body temperature) yielded very good AUC estimation in the test (relative bias/RMSE = 0.43/7.69%) and validation sets (relative bias/RMSE = 4.61/6.63%). The XGBoost ML model developed allowed accurate estimation of daptomycin AUC using C0, C1h, and a few covariates and could be used for exposure estimation and dose adjustment. This ML approach can facilitate the conduct of future therapeutic drug monitoring (TDM) studies.

Identifiants

pubmed: 38501807
doi: 10.1128/aac.01415-23
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0141523

Auteurs

Cyrielle Codde (C)

Service de Maladies Infectieuses et Tropicales, CHU Dupuytren, Limoges, France.

Florence Rivals (F)

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Dupuytren, Limoges, France.

Alexandre Destere (A)

Service de Pharmacologie et Pharmacovigilance, CHU, Nice, France.

Yeleen Fromage (Y)

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Dupuytren, Limoges, France.

Marc Labriffe (M)

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Dupuytren, Limoges, France.
Inserm, Univ. Limoges, CHU Limoges, Pharmacology & Toxicology, Limoges, France.

Pierre Marquet (P)

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Dupuytren, Limoges, France.
Inserm, Univ. Limoges, CHU Limoges, Pharmacology & Toxicology, Limoges, France.

Clément Benoist (C)

Inserm, Univ. Limoges, CHU Limoges, Pharmacology & Toxicology, Limoges, France.

Laure Ponthier (L)

Inserm, Univ. Limoges, CHU Limoges, Pharmacology & Toxicology, Limoges, France.

Jean-François Faucher (J-F)

Service de Maladies Infectieuses et Tropicales, CHU Dupuytren, Limoges, France.

Jean-Baptiste Woillard (J-B)

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Dupuytren, Limoges, France.
Inserm, Univ. Limoges, CHU Limoges, Pharmacology & Toxicology, Limoges, France.

Classifications MeSH